Aktien Sensor

Takeda Pharmaceutical’s stock price has been highly volatile, fluctuating between a 52-week high of 4573 JPY and a low of 3852 JPY.

Agilent Technologies Inc. showcased its latest products and innovations at HPLC 2025, highlighting its industry leadership and financial performance.

Merck KGaA’s stock price may be declining, but the company’s strong fundamentals, including a robust financial foundation and significant research and development efforts, position it for long-term success.

Regeneron Pharmaceuticals has made a groundbreaking breakthrough in cancer treatment with the FDA approval of Lynozyfic, a new medication for multiple myeloma.

Novartis AG’s key medication, Cosentyx, has failed to meet its primary endpoint in a Phase III study, leading to a decline in sales expectations and potential financial impact on the company.

Haleon PLC has broken ground on a £130m Global Oral Health Innovation Centre in Weybridge, Surrey, marking a major milestone in the company’s commitment to oral health research and innovation.

Amgen Inc. has made significant strides in research and development, unveiling promising results for its MariTide treatment and solidifying its position as a leader in the biotechnology industry.

Mettler-Toledo International Inc.’s stock price has increased moderately over the past year, outperforming some investment returns.

Lonza Group AG’s stock price has remained relatively stable despite a marginal loss in the Swiss market, thanks to its successful partnerships with pharmaceutical, biotech, and nutrition industries.

Sartorius Stedim Biotech has released financial updates, including a new high stock price and a liquidity contract, indicating a stable and active market for its shares.